Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Tango Therapeutics Inc. — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $382.97M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 9.8× JPMorgan Diversified Return International Eqty ETF's market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 1,797). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 121 Days and Tango Therapeutics Inc. for 0 Days on average.
| JPIN | TNGX | |
|---|---|---|
Market Cap | $382.97M | $3.75B |
Volume | 1,797 | 9,619,106 |
52-Week High | $77.80 | $32.90 |
52-Week Low | $65.86 | $7.50 |
Typical Hold Time | 121 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.52, up 0.65% today. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though the RSI suggests potential oversold conditions. The ETF provides broad exposure to international large-cap value stocks. A dividend of $0.51 is scheduled for payment in September 2026.
The outlook is cautious due to strong bearish technical signals. The primary opportunity lies in the ETF's international diversification and value focus, but risks include global market volatility and the current negative momentum. Investors should weigh the oversold RSI against the dominant sell signals.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
